Maqsood Shafaq, Badar Farhana, Hameed Abdul
Department of Medical Oncology, Shaukat Khanum Cancer Hospital and Research Centre, Lahore, Pakistan. Email:
Asian Pac J Cancer Prev. 2017 Jul 27;18(7):1833-1837. doi: 10.22034/APJCP.2017.18.7.1833.
Background and Purpose: Patients with hematological malignancies admitted to an intensive care unit (ICU) generally have a high mortality rate. The aim of our study was to assess the characteristics and outcomes of such patients and to identify factors predicting ICU mortality. Material and Methods: This retrospective chart review was conducted in the intensive care unit (ICU) of Shaukat Khanum Memorial Cancer Hospital and Research Centre over a period of 5 years, from January 2010 to January 2015. Results: Characteristics :A total of 213 patients were included in this study. There were 150 (70.4%) males and 63 (29.6%) females with the median age of 36 years (18-88 years). Main diagnosis was non- Hodgkin lymphoma in 127 (59.6%) followed by Hodgkin’s disease in 27 (12.7%) and acute myeloid leukemia in 16 (7.5%). Most of the patients 154 (72.3%) were on active chemotherapy at the time of admission to ICU, while 28 patients (13.1%) had newly diagnosed disease and 22 (10.3%) featured either relapsed or progressive disease. The most common reason for admission to ICU was a combination of respiratory failure with septic shock (29.6%) followed by septic shock alone (19.7%) and acute respiratory failure (13.1%). Other causes included acute renal failure, alone (7.5%) or in combination with respiratory or circulatory collapse (10.8%) and central nervous system involvement (5.6%). The majority of admissions to ICU occurred between days one and five of admission to a ward (46.5%, n=99) whereas 49 (23%) were taken directly to the ICU. Mainstay of treatment in 38.5% of patients included both invasive ventilation and vasopressor support along with other supportive care like fluids and antibiotics. 23.5% received only supportive management. Duration of stay for 150 (70.4%) patients was between one to seven days. Outcomes: A total of 119 (55.9 %) patients expired while in ICU, while 14 (6.6%) died in hospital after being transferred out of ICU. ICU survival was 44.1% whereas hospital survival was 37.5%. After discharge from hospital in a stable condition, 18 (8.5%) patients were lost to follow up and 62 (29%) patients were alive after thirty days. A total of 33 (15.4 %) of patients survived for at least one year after ICU admission. Some 21 (9.8%) are still alive and healthy after a minimum median follow up of one and a half years. Predictors of Mortality: Overall, mechanical ventilation was required in 61% of patients. Out of the patients who expired, 92.4% required intubation, in contrast to 21.3% for those who survived the ICU stay. Involvement of three or more organs was apparent in 12.8% of improved patients and 70.6% of those who died during ICU stay. Neutropenia did not appear to be a major discriminatory factor, with 33% of improved and 42.9% of expired patients being neutropenic at the time of admission to ICU. The majority of patients from both the improved and expired group required intubation and vasopressors from day one onwards. Conclusions: Admission of patients with hematological malignancies to the intensive care unit is associated with poor outcome and high mortality. Identifying the patients who can benefit from aggressive care and prolonged ICU support is important especially when it comes to countries like ours with limited resources and major financial restraints. Multi-organ damage and requirement of invasive ventilation are two main predictors of increased mortality. Neutropenia is also associated with adverse outcome; however, the difference is not as significant as for the other two factors.
入住重症监护病房(ICU)的血液系统恶性肿瘤患者通常死亡率较高。本研究的目的是评估此类患者的特征及预后,并确定预测ICU死亡率的因素。材料与方法:本回顾性病历审查在2010年1月至2015年1月的5年期间于沙卡特·汗姆纪念癌症医院及研究中心的重症监护病房进行。结果:特征:本研究共纳入213例患者。其中男性150例(70.4%),女性63例(29.6%),中位年龄为36岁(18 - 88岁)。主要诊断为非霍奇金淋巴瘤127例(59.6%),其次是霍奇金病27例(12.7%)和急性髓系白血病16例(7.5%)。大多数患者154例(72.3%)在入住ICU时正在接受积极化疗,而28例患者(13.1%)为新诊断疾病,22例(10.3%)为复发或进展性疾病。入住ICU最常见的原因是呼吸衰竭合并感染性休克(29.6%),其次是单纯感染性休克(19.7%)和急性呼吸衰竭(13.1%)。其他原因包括急性肾衰竭,单独出现(7.5%)或与呼吸或循环衰竭合并出现(10.8%)以及中枢神经系统受累(5.6%)。大多数患者在病房入住的第1天至第5天之间入住ICU(46.5%,n = 99),而49例(23%)直接被送往ICU。38.5%的患者的主要治疗方法包括有创通气和血管活性药物支持以及其他支持性治疗,如补液和使用抗生素。23.5%的患者仅接受支持性治疗。150例(70.4%)患者的住院时间为1至7天。预后:共有119例(55.9%)患者在ICU期间死亡,14例(6.6%)患者在转出ICU后在医院死亡。ICU生存率为44.1%,而医院生存率为37.5%。出院病情稳定后,18例(8.5%)患者失访,62例(29%)患者在30天后仍存活。共有33例(15.4%)患者在入住ICU后至少存活1年。约21例(9.8%)患者在至少中位随访1.5年后仍存活且健康。死亡率预测因素:总体而言,61%的患者需要机械通气。在死亡患者中,92.4%需要插管,而在ICU存活的患者中这一比例为21.3%。12.8%病情好转的患者和70.6%在ICU期间死亡的患者出现三个或更多器官受累。中性粒细胞减少似乎不是一个主要的鉴别因素,入住ICU时,病情好转的患者中有33%为中性粒细胞减少,死亡患者中有42.9%为中性粒细胞减少。从第1天起,病情好转组和死亡组的大多数患者都需要插管和使用血管活性药物。结论:血液系统恶性肿瘤患者入住重症监护病房预后不良且死亡率高。确定哪些患者能从积极治疗和延长的ICU支持中获益很重要,尤其是在像我们这样资源有限且资金严重受限的国家。多器官损害和有创通气需求是死亡率增加的两个主要预测因素。中性粒细胞减少也与不良预后相关;然而,其差异不如其他两个因素显著。